We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Therapy Cures Nicotine Addiction in Mouse Model

By LabMedica International staff writers
Posted on 10 Jul 2012
A novel gene-therapy approach has been used to treat nicotine addiction in a mouse model that mimics chronic cigarette smoking in humans.

Addiction to the nicotine in cigarette smoke prevents many smokers from quitting. To overcome this addiction investigators at Weill Cornell Medical College (New York, NY, USA) developed a genetics-based vaccine. They incorporated the gene for an antinicotine monoclonal antibody into an adeno-associated virus (AAV). The vector, which expressed the gene for a full-length, high-affinity, antinicotine antibody derived from the Fab fragment of the antinicotine monoclonal antibody NIC9D9 was designed to infect liver cells and then manufacture the antibody.

The vector was administered to a population of laboratory mice. Results published in the June 27, 2012, online edition of the journal Science Translational Medicine revealed that in the treated mice blood concentrations of the antinicotine antibody were dose-dependent, and the antibody showed high specificity and affinity for nicotine. The antibody shielded the brain from systemically administered nicotine, reducing brain nicotine concentrations to 15% of those in control mice. The amount of nicotine sequestered in the serum of vector-treated mice was more than seven times greater than that in untreated mice, with 83% of serum nicotine bound to immunoglobulin G. Treatment with the vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate, and locomotor activity.

"Our vaccine allows the body to make its own monoclonal antibodies against nicotine, and in that way, develop a workable immunity," said senior author Dr. Ronald G. Crystal, professor of genetic medicine at Weill Cornell Medical College." As far as we can see, the best way to treat chronic nicotine addiction from smoking is to have these Pacman-like antibodies on patrol, clearing the blood as needed before nicotine can have any biological effect."

"While we have only tested mice to date, we are very hopeful that this kind of vaccine strategy can finally help the millions of smokers who have tried to stop, exhausting all the methods on the market today, but find their nicotine addiction to be strong enough to overcome these current approaches," said Dr. Crystal. "Smoking affects a huge number of people worldwide, and there are many people who would like to quit, but need effective help. This novel vaccine may offer a much-needed solution."

Related Links:

Weill Cornell Medical College


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT

Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more